Report Overview

The Vaccines market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Vaccination is the most powerful and cost-effective way to protect millions of population against diseases. Vaccines have a potential to eliminate life-threatening infectious diseases that are prevalence in Kenya. Vaccines are administered for diseases like Tuberculosis, Malaria, Polio, Chicken pox and other infectious diseases that are highly prevalent in Kenya. In Kenya, approximately 77% of children aged 12-23 months are fully vaccinated with some districts reporting even lower levels of coverage. Coverage for specific antigens was BCG (99.5%), OPV0 (97.6%), OPV 1(98.7%), OPV2 (96.6%), OPV3 (90.5%), Penta 1(98.9), Penta 2 (96.6%), Penta 3 (90.0%), Measles (77.4%).



Market Drivers

The market is majorly driven by the rising prevalence of infectious disease in Kenya. In 2019, the Kenya national malaria incidence was reported at 125.92 cases per 1000 population.

Increased government funding for the production of vaccines, increased business efforts to boost R&D on vaccines, and the growing emphasis on immunisation has led to enormous growth in the vaccine market.

Government in partnership with pharmaceutical companies are making enormous efforts in establishing arrangements for the development of vaccines.

However, the pandemic has brought a halt in the regular immunization programs and led to decrease in the vaccination rate which has generated load on the healthcare systems.